Immune Response Dynamics and Biomarkers in COVID-19 Patients
Authors:
- Maral RanjbarMRMaral Ranjbar
- Ruth P. CusackRCRuth P. Cusack
- Christiane E. WhetstoneCWChristiane E. Whetstone
- Danica L. BristerDBDanica L. Brister
- Jennifer WattieJWJennifer Wattie
- Lesley WiltshireLWLesley Wiltshire
- Nadia AlsajiNANadia Alsaji
- Jennifer Le RouxJRJennifer Le Roux
- Eric ChengECEric Cheng
- Thivya SrinathanTSThivya Srinathan
- Terence HoTHTerence Ho
- Roma SehmiRSRoma Sehmi
Open Access
- 11 June 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (12) , 6427
Abstract
Background: The immune response dynamics in COVID-19 patients remain a subject of intense investigation due to their implications for disease severity and treatment outcomes. We examined changes in leukocyte levels, eosinophil activity, and cytokine profiles in patients hospitalized with COVID-19. Methods: Serum samples were collected within the first 10 days of hospitalization/confirmed infection and analyzed for eosinophil granule proteins (EGP) and cytokines. Information from medical records including comorbidities, clinical symptoms, medications, and complete blood counts were collected at the time of admission, during hospitalization and at follow up approximately 3 months later. Results: Serum levels of eotaxin, type 1 and type 2 cytokines, and alarmin cytokines were elevated in COVID-19 patients, highlighting the heightened immune response (p < 0.05). However, COVID-19 patients exhibited lower levels of eosinophils and eosinophil degranulation products compared to hospitalized controls (p < 0.05). Leukocyte counts increased consistently from admission to follow-up, indicative of recovery. Conclusion: Attenuated eosinophil activity alongside elevated chemokine and cytokine levels during active infection, highlights the complex interplay of immune mediators in the pathogenesis COVID-19 and underscores the need for further investigation into immune biomarkers and treatment strategies.Keywords
Funding Information
- Division of Intramural Research, NIAID, NIH
This publication has 52 references indexed in Scilit:
- Categorization of COVID‐19 severity to determine mortality riskPharmacoepidemiology and Drug Safety, 2022
- Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19Cell Reports, 2021
- Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategiesSeminars in Immunopathology, 2021
- Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytesJournal of Leukocyte Biology, 2020
- Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19Journal of Allergy and Clinical Immunology, 2020
- Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 PatientsCell Host & Microbe, 2020
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19Cell, 2020
- The host immune response in respiratory virus infection: balancing virus clearance and immunopathologySeminars in Immunopathology, 2016
- The effects of glucocorticoids on human eosinophilsJournal of Allergy and Clinical Immunology, 1994
- Effect of steroids on immunoglobulin-induced eosinophil degranulationJournal of Allergy and Clinical Immunology, 1991